Background. A reduction in the incidence of genital warts (GWs) is one of the first markers of
the effectiveness of vaccination against human papillomavirus (HPV) at the population level …

Background. Reducing the number of doses in the human papillomavirus (HPV) vaccination
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …

Background Approximately 90% of genital warts (GWs) are caused by human
papillomavirus (HPV) types 6 and 11. Denmark has provided the quadrivalent HPV vaccine …

Background Denmark introduced the quadrivalent human papillomavirus vaccine into the
vaccination program for 12-to 15-year-old girls in 2008 to 2009. In 2012, the program was …

Background. More than 90% of genital warts (GW) cases are caused by human
papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the …

Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts (GW)
in women aged 14–23 years and to estimate the incidence of GW in the whole population …

Background Although the human papillomavirus (HPV) vaccine has been recommended in
Germany for girls since 2007, no organised vaccination programme was introduced and …

Objective: This study aimed to determine if the Australian human papillomavirus (HPV)
vaccination programme has had a population impact on presentations of genital warts …

Background The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV)
vaccine in preventing high-grade cervical lesions have been shown. However, data to …